Alere Stock Price, News & Analysis (NYSE:ALR)

Notice: This company has been marked as potentially delisted and may not be actively trading.
$50.99 0.00 (0.00 %)
(As of 12/17/2017 08:41 AM ET)
Previous Close$50.99
Today's Range$50.99 - $50.99
52-Week Range$34.41 - $51.00
VolumeN/A
Average Volume1.53 million shs
Market Capitalization$4.47 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.21

About Alere (NYSE:ALR)

Alere logoAlere Inc. is a provider of health information through diagnostic tests. The Company's segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its joint venture with The Procter & Gamble Company (P&G). The Company's professional diagnostic solutions allow patients and their healthcare providers to work together to manage patients' conditions over the continuum of care, from the hospital to home. The Company offers lines of drugs-of-abuse tests, reagent systems and laboratory testing options.

Receive ALR News and Ratings via Email

Sign-up to receive the latest news and ratings for ALR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryHealth Care Supplies
SectorHealthcare
SymbolNYSE:ALR
CUSIP01449J10
Phone+1-781-6473900

Debt

Debt-to-Equity Ratio2.43%
Current Ratio2.04%
Quick Ratio1.54%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($3.11)
Net IncomeN/A
Net Margins-16.86%
Return on Equity-33.39%
Return on Assets-6.72%

Miscellaneous

Employees9,700
Outstanding Shares87,580,000

Alere (NYSE:ALR) Frequently Asked Questions

What is Alere's stock symbol?

Alere trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALR."

How were Alere's earnings last quarter?

Alere Inc (NYSE:ALR) released its quarterly earnings results on Friday, November, 4th. The medical research company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.54 by $0.35. The medical research company had revenue of $582 million for the quarter, compared to the consensus estimate of $605.50 million. Alere had a negative return on equity of 33.39% and a negative net margin of 16.86%. The firm's revenue was down 3.6% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.10) EPS. View Alere's Earnings History.

Where is Alere's stock going? Where will Alere's stock price be in 2017?

4 equities research analysts have issued 12 month price objectives for Alere's shares. Their predictions range from $51.00 to $51.00. On average, they anticipate Alere's stock price to reach $51.00 in the next year. View Analyst Ratings for Alere.

What are Wall Street analysts saying about Alere stock?

Here are some recent quotes from research analysts about Alere stock:

  • 1. According to Zacks Investment Research, "Alere Inc., formerly known as Inverness Medical Innovations, Inc., provides products and services, which focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Alere is headquartered in Waltham, Massachusetts. " (8/17/2017)
  • 2. BTIG Research analysts commented, "Continued Growth in Infectious Disease Business Yesterday, Alere filed its preliminary unaudited 10-K and proxy statements following review of matters in South Korea and Japan, and expects to file their Form 10-K by June 15th, 2017. The preliminary financial statements included 4Q16 and FY2016 results, as well as re- statements for revenue recognition during 2014, 2015, and 2016. Topline preliminary 1Q17 financial results were also provided. The filing of the proxy indicates a decoupling process versus the 10-K filing, allowing the shareholder meeting to likely occur between mid-to-late July. The company must resolve outstanding accounting issues and file the 10K by June 15 th or face another negotiation with the creditors and bond holders. We remain Neutral as we continue to think that the deal with Abbott (ABT, Buy, $50PT) will close at the stated terms of $51 per share later this year." (5/24/2017)

Who are some of Alere's key competitors?

Who are Alere's key executives?

Alere's management team includes the folowing people:

  • Gregg J. Powers, Independent Chairman of the Board
  • Namal Nawana, President, Chief Executive Officer, Director
  • James F. Hinrichs, Chief Financial Officer, Executive Vice President
  • Daniella Cramp, Global President - Cardiometabolic Business Unit
  • Sanjay Malkani, Global President - Toxicology
  • Avi Pelossof, Global President - Infectious Disease Business Unit
  • Ellen Chiniara J.D., Senior Vice President, General Counsel, Chief Ethics and Compliance Officer, Secretary
  • Robert Hargadon, Senior Vice President - Global Human Resources
  • John Bridgen Ph.D., Senior Vice President - Business Development
  • Mark Gladwell, Senior Vice President - Global Operations

Who owns Alere stock?

Alere's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Davidson Kempner Capital Management LP (4.08%), Dimensional Fund Advisors LP (3.06%), OxFORD Asset Management LLP (2.15%), Alyeska Investment Group L.P. (1.83%), Gabelli Funds LLC (1.79%) and Magnetar Financial LLC (1.75%). View Institutional Ownership Trends for Alere.

Who sold Alere stock? Who is selling Alere stock?

Alere's stock was sold by a variety of institutional investors in the last quarter, including Cowen Inc., Omni Partners LLP, Segall Bryant & Hamill LLC, Ameriprise Financial Inc., Gamco Investors INC. ET AL, Dimensional Fund Advisors LP, Janus Henderson Group PLC and Cornerstone Capital Management Holdings LLC.. View Insider Buying and Selling for Alere.

Who bought Alere stock? Who is buying Alere stock?

Alere's stock was purchased by a variety of institutional investors in the last quarter, including OxFORD Asset Management LLP, Davidson Kempner Capital Management LP, Alyeska Investment Group L.P., Gabelli Funds LLC, State of Wisconsin Investment Board, P Schoenfeld Asset Management LP, Magnetar Financial LLC and California State Teachers Retirement System. View Insider Buying and Selling for Alere.

What is Alere's stock price today?

One share of Alere stock can currently be purchased for approximately $50.99.

How big of a company is Alere?

Alere has a market capitalization of $4.47 billion. Alere employs 9,700 workers across the globe.

How can I contact Alere?

Alere's mailing address is 51 Sawyer Rd Ste 200, WALTHAM, MA 02453-3448, United States. The medical research company can be reached via phone at +1-781-6473900.


MarketBeat Community Rating for Alere (ALR)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  276 (Vote Outperform)
Underperform Votes:  299 (Vote Underperform)
Total Votes:  575
MarketBeat's community ratings are surveys of what our community members think about Alere and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Alere (NYSE:ALR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.172.172.172.14
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $49.60$49.60$49.60$50.67
Price Target Upside: 1.78% downside1.78% downside1.74% upside3.93% upside

Alere (NYSE:ALR) Consensus Price Target History

Price Target History for Alere (NYSE:ALR)

Alere (NYSE:ALR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/19/2017Canaccord GenuityReiterated RatingHold$51.00LowView Rating Details
6/1/2017Jefferies GroupReiterated RatingHold$51.00MediumView Rating Details
5/24/2017BTIG ResearchReiterated RatingHoldLowView Rating Details
5/15/2017Craig HallumDowngradeBuy -> HoldLowView Rating Details
11/4/2016Goldman Sachs GroupLower Price TargetNeutral$45.00 -> $42.00N/AView Rating Details
7/12/2016Leerink SwannReiterated RatingBuy$56.00N/AView Rating Details
2/2/2016Raymond James FinancialDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 12/17/2015 forward)

Earnings

Alere (NYSE:ALR) Earnings History and Estimates Chart

Earnings by Quarter for Alere (NYSE:ALR)

Alere (NYSE ALR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/4/2016Q3 16$0.54$0.19$605.50 million$582.00 millionViewN/AView Earnings Details
9/6/2016Q216$0.58($0.46)$621.95 million$611.10 millionViewN/AView Earnings Details
8/17/2016Q116$0.56($0.18)$578.00 millionViewN/AView Earnings Details
8/8/2016Q415$0.58($0.28)$662.04 million$623.00 millionViewN/AView Earnings Details
11/4/2015Q315$0.55$0.49$646.29 million$602.00 millionViewN/AView Earnings Details
8/4/2015Q215$0.53$0.49$625.67 million$629.00 millionViewN/AView Earnings Details
5/5/2015Q115$0.49$0.57$612.93 million$610.40 millionViewN/AView Earnings Details
2/10/2015Q414$0.63$0.61$698.56 million$666.90 millionViewN/AView Earnings Details
10/28/2014Q314$0.52$0.48$743.30 million$736.20 millionViewN/AView Earnings Details
8/4/2014Q214$0.58$0.43$747.55 million$738.30 millionViewN/AView Earnings Details
4/29/2014Q114$0.55$0.55$738.70 million$716.60 millionViewN/AView Earnings Details
2/6/2014Q413$0.56$0.62$770.70 million$772.30 millionViewN/AView Earnings Details
10/29/2013Q313$0.53$0.59$737.66 million$753.90 millionViewN/AView Earnings Details
7/31/2013Q2 2013$0.48$0.64$720.24 million$764.00 millionViewN/AView Earnings Details
5/9/2013Q1 2013$0.51$0.53$727.66 million$739.20 millionViewN/AView Earnings Details
2/15/2013Q4 2012$0.57$0.55$714.75 million$755.80 millionViewN/AView Earnings Details
11/8/2012Q312$0.53$0.43$690.76 million$691.40 millionViewN/AView Earnings Details
8/8/2012$0.53($0.23)ViewN/AView Earnings Details
4/30/2012$0.67$0.77ViewN/AView Earnings Details
2/8/2012$0.71$0.74ViewN/AView Earnings Details
10/26/2011$0.57$0.67ViewN/AView Earnings Details
7/27/2011$0.58$0.46ViewN/AView Earnings Details
4/27/2011$0.61$0.61ViewN/AView Earnings Details
2/17/2011$0.66$0.71ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Alere (NYSE:ALR) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Alere (NYSE:ALR)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Alere (NYSE ALR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.66%
Institutional Ownership Percentage: 89.33%
Insider Trades by Quarter for Alere (NYSE:ALR)
Institutional Ownership by Quarter for Alere (NYSE:ALR)

Alere (NYSE ALR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/1/2016Melissa GuerdanSVPSell2,500$54.00$135,000.00View SEC Filing  
11/13/2015Robert Bernard HargadonSVPBuy1,000$38.99$38,990.00View SEC Filing  
11/12/2015James F HinrichsCFOBuy10,000$39.97$399,700.00View SEC Filing  
9/3/2015Mark GladwellVPSell2,651$52.27$138,567.77View SEC Filing  
9/3/2015Melissa GuerdanSVPSell5,135$52.00$267,020.00View SEC Filing  
9/1/2015Melissa GuerdanSVPSell5,000$50.48$252,400.00View SEC Filing  
8/31/2015Mark GladwellVPSell27,513$52.23$1,437,003.99View SEC Filing  
8/14/2015Sanjay MalkaniInsiderSell31,460$54.60$1,717,716.00View SEC Filing  
6/8/2015Sanjay MalkaniInsiderSell24,331$50.87$1,237,717.97View SEC Filing  
6/4/2015Sanjay MalkaniInsiderSell15,669$52.18$817,608.42View SEC Filing  
6/1/2015John BridgenSVPSell7,500$51.19$383,925.00View SEC Filing  
4/6/2015Melissa GuerdanSVPSell2,500$50.00$125,000.00View SEC Filing  
3/23/2015Melissa GuerdanSVPSell13,476$48.35$651,564.60View SEC Filing  
3/17/2015John BridgenSVPSell25,000$48.53$1,213,250.00View SEC Filing  
3/16/2015Carla FlakneCAOSell8,500$48.99$416,415.00View SEC Filing  
1/16/2015Carla FlakneCAOSell10,000$42.45$424,500.00View SEC Filing  
12/24/2014Don DudekDirectorBuy40,000$0.01$500.00
12/11/2014John BridgenSVPSell50,000$37.07$1,853,500.00View SEC Filing  
8/15/2014Dave TeitelCFOSell10,000$35.07$350,700.00View SEC Filing  
8/15/2013Dave TeitelCFOSell10,000$31.73$317,300.00View SEC Filing  
8/5/2013Michael Lester CottonInsiderSell12,500$33.82$422,750.00View SEC Filing  
5/31/2013Michael Lester CottonInsiderSell8,750$25.86$226,275.00View SEC Filing  
3/5/2013John QuelchDirectorSell20,220$23.49$474,967.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Alere (NYSE ALR) News Headlines

Source:
DateHeadline
Tracking Prem Watsas Fairfax Financial Holdings Portfolio - Q3 2017 Update - Seeking AlphaTracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q3 2017 Update - Seeking Alpha
seekingalpha.com - November 17 at 10:48 AM
Contrasting Alere (ALR) & Cogentix Medical (CGNT)Contrasting Alere (ALR) & Cogentix Medical (CGNT)
www.americanbankingnews.com - November 8 at 9:32 PM
Alere Inc (ALR) Given Consensus Rating of "Hold" by BrokeragesAlere Inc (ALR) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 6 at 3:46 AM
Public health care company to layoff 182, close two South Florida officesPublic health care company to layoff 182, close two South Florida offices
finance.yahoo.com - November 2 at 4:12 PM
Alere (ALR) and Its Rivals Head-To-Head AnalysisAlere (ALR) and Its Rivals Head-To-Head Analysis
www.americanbankingnews.com - October 29 at 3:08 AM
Alere (ALR) vs. Its Competitors Head to Head SurveyAlere (ALR) vs. Its Competitors Head to Head Survey
www.americanbankingnews.com - October 15 at 4:28 AM
Alere Inc. (ALR) Given Consensus Recommendation of "Hold" by BrokeragesAlere Inc. (ALR) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - October 12 at 4:46 AM
Contrasting Hansen Medical (HNSN) & Alere (ALR)Contrasting Hansen Medical (HNSN) & Alere (ALR)
www.americanbankingnews.com - October 7 at 6:30 PM
Alere (ALR) & Its Peers Head-To-Head ComparisonAlere (ALR) & Its Peers Head-To-Head Comparison
www.americanbankingnews.com - October 7 at 4:18 AM
Alere Inc. -- Moodys to withdraw Aleres ratings following debt redemptionAlere Inc. -- Moody's to withdraw Alere's ratings following debt redemption
finance.yahoo.com - October 5 at 6:13 PM
Alere Announces FDA Clearance For I Influenza A & B 2 Rapid Molecular TestAlere Announces FDA Clearance For I Influenza A & B 2 Rapid Molecular Test
www.nasdaq.com - October 2 at 3:36 PM
Alere (ALR) Announces FDA Clearance for Alere i Influenza A & B 2 Rapid Molecular TestAlere (ALR) Announces FDA Clearance for Alere i Influenza A & B 2 Rapid Molecular Test
www.streetinsider.com - October 2 at 3:36 PM
Alere Receives FDA Clearance for Alere™ i Influenza A & B 2 Rapid Molecular TestAlere Receives FDA Clearance for Alere™ i Influenza A & B 2 Rapid Molecular Test
finance.yahoo.com - October 2 at 3:36 PM
Corporate News Blog - Alere Announces Agreement with the US Department of Justice; Settles the Investigations Concerning Previous Foreign AcquisitionsCorporate News Blog - Alere Announces Agreement with the US Department of Justice; Settles the Investigations Concerning Previous Foreign Acquisitions
finance.yahoo.com - October 2 at 3:36 PM
FDA clears Aleres second-generation flu testFDA clears Alere's second-generation flu test
seekingalpha.com - October 2 at 11:25 AM
Alere (ALR) Announces FDA Clearance for Alere i Influenza A & B 2 Rapid Molecular Test - StreetInsider.comAlere (ALR) Announces FDA Clearance for Alere i Influenza A & B 2 Rapid Molecular Test - StreetInsider.com
www.streetinsider.com - October 2 at 7:31 AM
Alere Reaches Settlement With SECAlere Reaches Settlement With SEC
finance.yahoo.com - September 30 at 2:13 PM
Alere (ALR) Reports U.S. DOJ has Ended Investigation Into Sales, Sales Practices and Dealings with Certain 3rd PartiesAlere (ALR) Reports U.S. DOJ has Ended Investigation Into Sales, Sales Practices and Dealings with Certain 3rd Parties
www.streetinsider.com - September 30 at 2:13 PM
Abbott (ABT) Se to Close Alere (ALR) Takeover on October 3 - StreetInsider.comAbbott (ABT) Se to Close Alere (ALR) Takeover on October 3 - StreetInsider.com
www.streetinsider.com - September 29 at 8:20 PM
Alere Announces Agreement In Principle To Settle With U.S. DoJAlere Announces Agreement In Principle To Settle With U.S. DoJ
www.rttnews.com - September 29 at 3:19 PM
Alere Announces the U.S. Department of Justice Closes InvestigationAlere Announces the U.S. Department of Justice Closes Investigation
finance.yahoo.com - September 29 at 3:19 PM
Alere Reaches Analyst Target PriceAlere Reaches Analyst Target Price
www.nasdaq.com - September 29 at 3:19 PM
Alere Agrees To Pay More Than $13 Mln To Settle SEC Accounting Fraud ChargesAlere Agrees To Pay More Than $13 Mln To Settle SEC Accounting Fraud Charges
www.nasdaq.com - September 28 at 9:20 PM
Abbott wins U.S. antitrust approval to buy Alere with conditionsAbbott wins U.S. antitrust approval to buy Alere with conditions
www.reuters.com - September 28 at 4:17 PM
Alere to divest two product lines to get FTC signoff on Abbott merger; shares up 4%Alere to divest two product lines to get FTC signoff on Abbott merger; shares up 4%
seekingalpha.com - September 28 at 3:23 PM
Alere to pay $13M to settle SEC inquiry into revenue recognition issuesAlere to pay $13M to settle SEC inquiry into revenue recognition issues
seekingalpha.com - September 28 at 12:24 PM
Alere, Inc. – Value Analysis (NYSE:ALR) : September 21, 2017Alere, Inc. – Value Analysis (NYSE:ALR) : September 21, 2017
finance.yahoo.com - September 22 at 2:43 PM
Alere Inc. (ALR) Stock Rating Reaffirmed by Canaccord GenuityAlere Inc. (ALR) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - September 20 at 2:38 PM
Quidel Corp (QDEL) Gains After Revised Deal on Aleres (ALR) BNP ... - StreetInsider.comQuidel Corp (QDEL) Gains After Revised Deal on Alere's (ALR) BNP ... - StreetInsider.com
www.streetinsider.com - September 19 at 3:46 PM
Alere Inc. Declares Cash Dividend on its Series B Convertible ... - PR Newswire (press release)Alere Inc. Declares Cash Dividend on its Series B Convertible ... - PR Newswire (press release)
www.prnewswire.com - September 19 at 3:46 PM
Alere, Inc. breached its 50 day moving average in a Bullish Manner : ALR-US : September 19, 2017Alere, Inc. breached its 50 day moving average in a Bullish Manner : ALR-US : September 19, 2017
finance.yahoo.com - September 19 at 3:46 PM
Here's Why Quidel Corporation Stock Is Popping TodayHere's Why Quidel Corporation Stock Is Popping Today
finance.yahoo.com - September 19 at 3:46 PM
Alere Announces Intent to Voluntarily Delist Series B Convertible Perpetual Preferred Stock from the NYSE Conditioned Upon the Completion of its Acquisition by AbbottAlere Announces Intent to Voluntarily Delist Series B Convertible Perpetual Preferred Stock from the NYSE Conditioned Upon the Completion of its Acquisition by Abbott
finance.yahoo.com - September 18 at 9:11 PM
Mid-Day ETF Update: ETFs, Stocks Higher as Major Indices Reach Fresh All-Time HighsMid-Day ETF Update: ETFs, Stocks Higher as Major Indices Reach Fresh All-Time Highs
www.nasdaq.com - September 18 at 4:10 PM
Medical Research Stock Performance Review -- Agilent Technologies, Alere, Quintiles IMS, and Thermo Fisher ScientificMedical Research Stock Performance Review -- Agilent Technologies, Alere, Quintiles IMS, and Thermo Fisher Scientific
www.bizjournals.com - September 18 at 4:10 PM
Alere Inc. (ALR) Given Consensus Recommendation of "Hold" by AnalystsAlere Inc. (ALR) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 17 at 4:40 AM
ALERE INVESTIGATION INITIATED by Former Louisiana Attorney ... - Business Wire (press release)ALERE INVESTIGATION INITIATED by Former Louisiana Attorney ... - Business Wire (press release)
www.businesswire.com - September 16 at 3:33 PM
Head to Head Comparison: Fulgent Genetic (FLGT) vs. Alere (ALR)Head to Head Comparison: Fulgent Genetic (FLGT) vs. Alere (ALR)
www.americanbankingnews.com - September 11 at 1:08 PM
ALERE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick ...ALERE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick ...
www.prnewswire.com - September 9 at 2:12 AM
Alere, Inc. breached its 50 day moving average in a Bearish Manner : ALR-US : September 8, 2017Alere, Inc. breached its 50 day moving average in a Bearish Manner : ALR-US : September 8, 2017
finance.yahoo.com - September 8 at 4:06 PM
Alere (ALR) versus Boston Scientific Corporation (BSX) Head-To-Head SurveyAlere (ALR) versus Boston Scientific Corporation (BSX) Head-To-Head Survey
www.americanbankingnews.com - September 6 at 12:22 PM
ALERE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the ... - Business Wire (press release)ALERE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the ... - Business Wire (press release)
www.businesswire.com - September 2 at 2:25 AM
ALERE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alere Inc. - ALRALERE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alere Inc. - ALR
finance.yahoo.com - September 2 at 2:25 AM
Alere Inc. (ALR) Sees Large Growth in Short InterestAlere Inc. (ALR) Sees Large Growth in Short Interest
www.americanbankingnews.com - August 31 at 1:46 AM
New Strong Sell Stocks for August 28thNew Strong Sell Stocks for August 28th
finance.yahoo.com - August 28 at 3:51 PM
ETFs with exposure to Alere, Inc. : August 25, 2017ETFs with exposure to Alere, Inc. : August 25, 2017
finance.yahoo.com - August 25 at 5:21 PM
Alere Inc. (ALR) Receives Average Rating of "Hold" from AnalystsAlere Inc. (ALR) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - August 23 at 4:44 AM
Alere, Inc. :ALR-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017Alere, Inc. :ALR-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
finance.yahoo.com - August 16 at 3:48 PM
See what the IHS Markit Score report has to say about Alere Inc.See what the IHS Markit Score report has to say about Alere Inc.
finance.yahoo.com - August 12 at 3:34 PM
See what the IHS Markit Score report has to say about Alere Inc.See what the IHS Markit Score report has to say about Alere Inc.
finance.yahoo.com - August 12 at 3:34 PM

SEC Filings

Alere (NYSE:ALR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Alere (NYSE:ALR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Alere (NYSE ALR) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.